. . . "After a 10-second bolus dose of 150 mg/m2 of ETHYOL, renal excretion of the parent drug and its two metabolites was low during the hour following drug administration, averaging 0.69%, 2.64% and 2.22% of the administered dose for the parent, thiol and disulfide, respectively."@en . . . "Amifostine"@en . . . . "Amifostine"@en . "20537-88-6"@en . . . . . . . . . . "approved"@en . . . . . "8 minutes"@en . . . . . "Aminopropylaminoethyl Thiophosphate"@en . "Rat LD₅₀: 826 mg/kg"@en . . . . . . . . . "Gammaphos"@en . . . . "Ethyol"@en . . . . "investigational"@en . . . "Apaetp"@en . "For reduction in the cumulative renal toxicity in patients with ovarian cancer (using cisplatin) and moderate to severe xerostomia in patients undergoing post-operative radiation treatment for head and neck cancer."@en . "# Santini V, Giles FJ: The potential of amifostine: from cytoprotectant to therapeutic agent. Haematologica. 1999 Nov;84(11):1035-42. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/10553165"@en . . . "The thiol metabolite is responsible for most of the cytoprotective and radioprotective properties of amifostine. It is readily taken up by cells where it binds to and detoxifies reactive metabolites of platinum and alkylating agents as well as scavenges free radicals. Other possible effects include inhibition of apoptosis, alteration of gene expression and modification of enzyme activity."@en . "Ethiofos"@en . "Paul E. Kennedy, Roger A. Rajewski, John M. Baldoni, \"Crystalline amifostine compositions and methods of the preparation and use of same.\" U.S. Patent US5424471, issued April, 1979."@en . "Amifostine Ethiofos"@en . "Amifostina"@en . "SAPEP"@en . . " "@en . . . "Amifostinum"@en . . . "Humans and other mammals"@en . "A phosphorothioate proposed as a radiation-protective agent. It causes splenic vasodilation and may block autonomic ganglia. [PubChem]"@en . . . . "WR-1065"@en . . . . . .